

ASX/Media Release

## **Resignation of joint Company Secretary and Appointment of new joint Company Secretary**

**Immutep Limited (ASX: IMM; NASDAQ: IMMP) 4 January 2021:** ASX and NASDAQ listed biotechnology company Immutep Limited (“Immutep” or the “Company”), advises that Mr Tom Bloomfield has resigned as the joint Company Secretary of the Company and Ms Indira Naidu has been appointed as the new Joint Company Secretary, effective today. Ms Naidu together with Ms Deanne Miller are the persons responsible under Listing Rule 12.6 for communications with ASX.

Ms Naidu joined Immutep in June 2020 and is a member of Institute of Chartered Accountants Australia and New Zealand, and a member of Australian Institute of Company Directors. Her experiences include over 16 years of audit and assurance, followed by subsequent experience in finance, statutory reporting and corporate governance with Australian listed companies. She holds a Bachelor of Arts Degree in Accounting and Financial Management.

This announcement was authorised for release by the board of Immutep Limited.

### **About Immutep**

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website [www.immutep.com](http://www.immutep.com) or by contacting:

### **Australian Investors/Media:**

Catherine Strong, Citadel-MAGNUS  
+61 (0)406 759 268; [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

### **U.S. Media:**

Tim McCarthy, LifeSci Advisors  
+1 (212) 915.2564; [tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)